US Kidney Research Corporation (USKRC) - A Delaware C-Corp Formed in 2015 is a leader in artificial kidney research and development, recognized by American Society of Nephrology (ASN), KidneyX, and the US Department of Health and Human Services (HHS).
 

Since its founding, the company has been dedicated to the research and development of its flagship innovation, the world’s first waterless blood purifying device, as well as other related technologies. This cutting-edge device is paving the way toward the creation of an implantable artificial kidney, revolutionizing the future of renal treatment.

 

Unlike traditional dialysis, our pioneering waterless device eliminates the need for:

• Purified water

• Dialysate concentrate solutions

• Dialyzers

Whether used at home or in clinical settings, our system:

• Simplifies the entire blood purification process

• Provides real-time patient monitoring and analysis

For healthcare providers, our technology:

• Eliminates costly water purification infrastructure and disposables (dialyzers, dialysate solutions), resulting in significant savings in overhead costs

For home users, there is no need for:

• A water purification system

• Installation of a drainage system

• Disposables
   

Ecological Merits - Carbon Footprint Reduction

• Each year, 6.2 billion gallons of contaminated water from hemodialysis are released into the U.S. drainage system. Our waterless device could greatly reduce this impact.

• Eliminates energy consumed in purifying water through reverse osmosis

• Eliminates production of dialyzers and dialysate

• Eliminates the transportation of dialysis-related supplies, reducing emissions

• Will substantially minimize the amount of plastic dialyzer waste sent to landfills

 

The company’s initial focus is on creating a portable artificial kidney for use at home or clinics, with plans to miniaturize the technology into an implantable device that replicates natural kidney functions. This paradigm-shifting approach could transform renal replacement therapy, offering patients greater mobility, independence, and quality of life.

​

US Kidney Research Corporation has a continuous subcontracting agreement with the University of Arkansas to conduct research under our direction. The university was chosen for its leading researchers, who are experts in electrodeionization, the core methodology behind our primary technology. US Kidney Research Corporation holds exclusive ownership of all intellectual property rights.

 

Highlights:
 

First in the world to create synthetic urine using a new blood purifying technology that involves filtration and ion transport processes similar to the native kidney. Animal studies were performed at Noble Life Sciences in Maryland using our latest prototype.

650k award winner of the international KidneyX Phase 1 Artificial Kidney Contest for our novel development of a dialysate-free waterless portable and implantable artificial kidney technology. KidneyX is sponsored by the American Society of Nephrology (ASN) and the U.S. Department of Health and Human Services (HHS). 

75k award winner of KidneyX Redesign Dialysis Phase 1 contest sponsored in partnership by US Dept. of Health and Human Services and the American Society of Nephrology.

Invited as Guest speaker by International Federation for Artificial Organs (IFAO) to present at the American Society for Implantable Artificial Organs (ASAIO) Chicago conference in June 2020 and in Washington DC, June 2021.

 

Interviewed twice by BioWorld Magazine; listed on GE Website (The Five Coolest Things on Earth - synthetic kidney); numerous online articles published about US Kidney Research Corporation

 

Science article published in Nature, the premier science journal in the world. "Simulating nephron ion transport function using activated wafer electrodeionization."

 

Nature Published Journal Article - "Could implantable artificial kidneys end the need for dialysis?"

 

New Ultra-filter Membrane - Detailed in Scientific Reports (a Nature Publication). "High flux novel polymeric membrane for renal applications."

​

GRANTED PATENTS

United States 

China 

India 

Japan 

S. Korea 

UK 

Spain       

Hong Kong 

Singapore 

Australia 

Mexico 

EU Unitary – 17 countries: Austria, Belgium, Bulgaria, Denmark, Estonia, Finland, France, Germany, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Portugal, Slovenia, Sweden

PCT international patents pending: Canada

 

Quality Management System ISO 13485:2016 for Medical Devices in place.

While developing our dialysis replacement technology, our primary research has led to other inventions:                                                                                                                                                 
1. New superior ultra-filter membrane material for use in bio-medical and non-medical applications. Use Examples: Dialyzers and other bio-medical devices (human and veterinarian), wastewater filtration, laboratories - e.g. vaccine water purifying, and in the food & beverage industries.

 

2. Coating: We are developing a new anti-coagulant coating that can be used to keep medical device tubing, blood testing equipment, and catheters from clotting. Anti-coagulant blood thinners given to patients prior to dialysis would no longer be needed.   

                                                                                 

3. Peritoneal Dialysis: Beginning development of a new method using our technology to regenerate peritoneal dialysis solution in PD patients, reducing the number of peritoneal solutions required by the industry resulting in significant cost savings.               

 

--        ​

Our revolutionary waterless technology for purifying the blood of patients with end stage kidney disease has the potential to completely replace current dialysis procedures in an industry that has not changed its methodology in decades. The technology is leading to a truly implantable artificial kidney. In collaboration with advisors and research scientists from UCLA and the University of Arkansas. 

 

​US Kidney Research Corporation has made significant progress in achieving its goals.

It is our intention to bring this new technology to clinical practice and help all those suffering from acute kidney injury(AKI) and end stage renal disease (ESRD).

 

 

​